3.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.795
Aprire:
$3.83
Volume 24 ore:
3.52M
Relative Volume:
1.75
Capitalizzazione di mercato:
$1.19B
Reddito:
$248.37M
Utile/perdita netta:
$11.74M
Rapporto P/E:
79.80
EPS:
0.05
Flusso di cassa netto:
$18.24M
1 W Prestazione:
+6.40%
1M Prestazione:
-3.16%
6M Prestazione:
-40.80%
1 anno Prestazione:
-26.52%
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Confronta MNKD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MNKD
Mannkind Corp
|
3.99 | 1.19B | 248.37M | 11.74M | 18.24M | 0.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-10 | Iniziato | Mizuho | Outperform |
2025-02-10 | Iniziato | Wedbush | Outperform |
2024-12-20 | Iniziato | Wells Fargo | Overweight |
2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2024-09-09 | Ripresa | Leerink Partners | Outperform |
2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
2023-10-10 | Iniziato | Wedbush | Outperform |
2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
2019-12-24 | Iniziato | Oppenheimer | Outperform |
2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
2019-05-14 | Iniziato | BTIG Research | Buy |
2019-03-04 | Iniziato | SVB Leerink | Outperform |
2019-02-22 | Iniziato | SVB Leerink | Outperform |
2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
2017-10-10 | Iniziato | H.C. Wainwright | Buy |
2017-10-06 | Reiterato | Maxim Group | Buy |
2017-08-11 | Iniziato | Maxim Group | Buy |
2016-05-10 | Reiterato | Piper Jaffray | Underweight |
2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
2016-01-06 | Reiterato | Piper Jaffray | Underweight |
2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
2015-05-11 | Reiterato | MLV & Co | Hold |
2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind stock hits 52-week low at $3.70 - Investing.com
Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga
Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus
MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa
MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia
Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech
MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com
MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada
MannKind to present inhaled insulin study at ADA event - Investing.com
Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23 - Yahoo Finance
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia
MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
Type 1 Diabetes Didn't Stop This INDYCAR Driver: Conor Daly Inspires Detroit Youth Before Grand Prix - Stock Titan
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com
MannKind To Present At RBC Capital Markets Conference; Webcast At 8:00 AM ET - Nasdaq
Most adults with type 1 diabetes using inhaled insulin increase daily dose over 30 weeks - Healio
MannKind corp director Steven Binder sells $375,875 in stock By Investing.com - Investing.com Nigeria
MannKind EVP David Thomson sells shares worth $150,597 By Investing.com - Investing.com India
MannKind EVP David Thomson sells shares worth $150,597 - Investing.com
MannKind corp director Steven Binder sells $375,875 in stock - Investing.com
MannKind CMO steps down, transition plan set - Investing.com
MannKind to Present at Upcoming Investor Conferences - The Globe and Mail
MannKind Corporation (NASDAQ:MNKD) Q1 2025 Earnings Call Transcript - Insider Monkey
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
MannKind: Q1 Earnings Snapshot - MySA
Earnings call transcript: MannKind Q1 2025 revenue beats, stock dips - Investing.com
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Gr - GuruFocus
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Growth | MNKD Stock News - GuruFocus
MannKind Corp Q1 2025 Earnings: EPS Meets Estimates at $0.04, Revenue Surpasses Expectations at $78 Million - GuruFocus
MannKind Corporation Reports First Quarter 2025 Financial Results - TradingView
MANNKIND CORP SEC 10-Q Report - TradingView
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Ex - GuruFocus
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 - The Globe and Mail
The Potential Rise in the Price of Mannkind Corp (MNKD) following insiders activity - knoxdaily.com
Solidion Technology Inc’s latest rating changes from various analysts - knoxdaily.com
MNKD (Mannkind Corp) may reap gains as insiders became active recently - knoxdaily.com
Mannkind Corp (MNKD) is looking forward to a strong quarter - Sete News
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):